By Fineline Cube InventisBio Co., Limited (SHA: 688382) this week filed for an initial public offering (IPO) to the Hong Kong Stock Exchange, seeking to raise capital to advance its pipeline of 8 products across oncology, autoimmune, and metabolic diseases, including two commercialized assets and three clinical‑stage candidates.
Company & Offering Overview
| Item | Detail |
|---|---|
| Company | InventisBio Co., Limited (688382.SH) |
| Founded | 2013 |
| IPO Venue | Hong Kong Stock Exchange |
| Focus Areas | Oncology, autoimmune diseases, metabolic disorders |
| Pipeline | 2 commercialized, 3 clinical‑stage, 3 pre‑clinical assets |
| Filing Date | Week of 13 Jan 2026 |
| Use of Proceeds | Clinical development, manufacturing scale‑up, commercial expansion |
Differentiated Pipeline Summary
| Category | Asset | Target/Mechanism | Stage | Indication |
|---|---|---|---|---|
| Commercialized | Befotertinib | EGFR T790M | Marketed | NSCLC (China) |
| Garsorasib | KRAS G12C | Marketed | NSCLC (China) | |
| Core Clinical | D‑2570 | TYK2 inhibitor | Phase II | Autoimmune |
| D‑0502 | SERD | Phase II | Breast cancer | |
| Clinical | D‑0120 | Undisclosed | Phase I | Oncology |
| Pre‑clinical | YF087, YF550, YF057 | Undisclosed | Pre‑clinical | Oncology/metabolic |
Market Opportunity & Strategic Positioning
- Commercial Validation: Befotertinib and garsorasib generated ¥1.2 billion in 2025 sales, demonstrating commercial execution capability in China’s competitive oncology market
- Cancer Focus: Befotertinib addresses EGFR T790M NSCLC (30 % of China’s 800,000 annual NSCLC cases), while garsorasib targets KRAS G12C (~12 % of NSCLC)
- Autoimmune Pipeline: D‑2570 (TYK2 inhibitor) enters a ¥45 billion market dominated by JAK inhibitors, offering improved safety profile
- Manufacturing: InventisBio’s Shanghai facility (15,000 L capacity) supports clinical and early commercial supply; IPO proceeds will fund Phase III scale‑up
- Global Ambitions: Hong Kong listing positions company for ex‑China licensing and global clinical trials
Forward‑Looking Statements
This brief contains forward‑looking statements regarding IPO completion, pipeline advancement, and commercial forecasts. Actual results may differ due to regulatory review timelines, market conditions, and clinical trial outcomes.-Fineline Info & Tech